A Case of Multiple Tuberculosis Associated with Infliximab Therapy in Crohn's Disease.
김희욱; 장성일; 이상인; 박효진; 변민광; 윤영훈; 김번
대한내과학회지, Vol.83(3) : 337~341, 2012
Infliximab, a tumor necrosis factor-alpha (TNF-alpha) inhibitor, has been approved for the treatment of a variety of inflammatory illnesses, including Crohn's disease. However, infliximab can increase the risk of reactivation of latent tuberculosis (Tbc) infection by affecting host immune responses. Therefore, a screening test should be performed before the initiation of infliximab therapy, and patients with evidence of latent infection should be treated with prophylactic anti-Tbc therapy. Here, we report a case of multifocal disseminated tuberculosis after treatment with infliximab in a patient diagnosed with Crohn's disease who had no past history of Tbc and showed a negative screening test.